Multiparameter flow cytometric analysis reveals low percentage of bone marrow hematogones in myelodysplastic syndromes

American Journal of Clinical Pathology

Volumn 129, Issue 2, 2008, Pages 300-308

  Maftoun Banankhah, Sepideh ^a   Maleki, Atousa ^a   Karandikar, Nitin J ^a   Arbini, Arnaldo A ^a   Fuda, Franklin S ^a   Wang, Huan You ^a   Chen, Weina ^a,b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cytogenetics; Hematogones; Multiparameter flow cytometry; Myelodysplastic syndromes

Indexed keywords

ADULT; AGED; ARTICLE; BONE MARROW; CONTROLLED STUDY; CYTOPENIA; ERYTHROBLAST; ERYTHROCYTE COUNT; ERYTHROID PRECURSOR CELL; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN TISSUE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; B LYMPHOCYTE; BONE MARROW CELL; CASE CONTROL STUDY; EVALUATION; IMMUNOPHENOTYPING; METHODOLOGY; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; B-LYMPHOCYTES; BONE MARROW CELLS; CASE-CONTROL STUDIES; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES;

EID: 40449134575     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/4W2G3NDXUPG5J33N     Document Type: Article

References (33)

1. Aul C, Germing U, Gattermann N, et al. Increasing incidence of myelodysplastic syndromes: real or fictitious? Leuk Res. 1998;22:93-100.
2. Burning RD, Bennett JM, Flandrin G, et al. Myelodysplastic syndromes: introduction. In: Jaffe ES, Harris NL, Stein H, et al, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:63-67. World Health Organization Classification of Tumours.
3. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292-2302.
4. Ramos F, Fernandez-Ferrero S, Suarez D, et al. Myelodysplastic syndrome: a search for minimal diagnostic criteria. Leuk Res. 1999;23:283-290.
5. List A F, Vardiman J, Issa J P, et al. Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2004:297-317.
6. Sternberg A, Killick S, Littlewood T, et al. Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. Blood. 2005;106:2982-2991.
7. Pellagatti A, Cazzola M, Giagounidis AA, et al. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon- stimulated genes and correlation to FAB subtype and karyotype. Blood. 2006;108:337-345.
8. Vyas P, Sternberg A. Characterization of the hemopoietic defect in early stages of the myelodysplastic syndromes. Adv Enzyme Regul. 2006;46:98-112.
9. Ogata K, Kishikawa Y, Satoh C, et al. Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood. 2006;108:1037-1044.
10. McKenna RW, Washington LT, Aquino DB, et al. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood. 2001;98:2498-2507.
11. Schuurmans Stekhoven JH, Langenhuysen CA, Bakkeren JA, et al. Morphology and incidence of the "posttherapeutic lymphoid cell" in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1986;124:46-52.
12. Rimsza LM, Larson RS, Winter SS, et al. Benign hematogone-rich lymphoid proliferations can be distinguished from B-lineage acute lymphoblastic leukemia by integration of morphology, immunophenotype, adhesion molecule expression, and architectural features. Am J Clin Pathol. 2000;114:66-75.
13. Muehleck SD, McKenna RW, Gale PF, et al. Terminal deoxynucleotidyl transferase (TdT)-positive cells in bone marrow in the absence of hematologic malignancy. Am J Clin Pathol. 1983;79:277-284.
14. Butcher BW, Wilson KS, Kroft SH, et al. Acute leukemia with B-lymphoid and myeloid differentiation associated with an inv(5)(q13q33) in an adult patient. Cancer Genet Cytogenet. 2005;157:62-66.
15. Mitelman F. ISCN 1995: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 1995.
16. Steensma D P, Dewald GW, Hodnefield JM, et al. Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia? Leuk Res. 2003;27:235-242.
17. Loken MR, Shah VO, Dattilio KL, et al. Flow cytometric analysis of human bone marrow, II: normal B lymphocyte development. Blood. 1987;70:1316-1324.
18. Ryan DH, Chapple CW, Kossover SA, et al. Phenotypic similarities and differences between CALLA-positive acute lymphoblastic leukemia cells and normal marrow CALLA-positive B cell precursors. Blood. 1987;70:814-821.
19. Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry. 1999;38:139-152.
20. McKenna RW, Asplund SL, Kroft SH. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) and neoplastic lymphoblasts by 4-color flow cytometry. Leuk Lymphoma. 2004;45:277-285.
21. Chen W, Karandikar NJ, McKenna RW, et al. Stability of leukemia-associated immunophenotypes in precursor B-lymphoblastic leukemia/lymphoma: a single institution experience. Am J Clin Pathol. 2007;127:39-46.
22. Stetler-Stevenson M, Arthur DC, Jabbour N, et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood. 2001;98:979-987.
23. Wells DA, Benesch M, Loken MR, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood. 2003;102:394-403.
24. Kussick SJ, Wood BL. Using 4-color flow cytometry to identify abnormal myeloid populations. Arch Pathol Lab Med. 2003; 127:1140-1147.
25. Xu Y, McKenna RW, Karandikar NJ, et al. Flow cytometric analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukemia from reactive monocytosis. Am J Clin Pathol. 2005;124:799-806.
26. LeBien T W. Fates of human B-cell precursors. Blood. 2000;96:9-23.
27. Ryan DH, Nuccie BL, Ritterman I, et al. Expression of interleukin-7 receptor by lineage-negative human bone marrow progenitors with enhanced lymphoid proliferative potential and B-lineage differentiation capacity. Blood. 1997;89:929-940.
28. Muller-Sieburg CE, Cho RH, Karlsson L, et al. Myeloid-biased hematopoietic stem cells have extensive self-renewal capacity but generate diminished lymphoid progeny with impaired IL-7 responsiveness. Blood. 2004;103:4111-4118.
29. Amin HM, Jilani I, Estey EH, et al. Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome. Blood. 2003;102:1866-1868.
30. van Kamp H, Fibbe WE, Jansen R P, et al. Clonal involvement of granulocytes and monocytes, but not of T and B lymphocytes and natural killer cells in patients with myelodysplasia: analysis by X-linked restriction fragment length polymorphisms and polymerase chain reaction of the phosphoglycerate kinase gene. Blood. 1992;80:1774-1780.
31. Kibbelaar RE, van Kamp H, Dreef EJ, et al. Combined immunophenotyping and DNA in situ hybridization to study lineage involvement in patients with myelodysplastic syndromes. Blood. 1992;79:1823-1828.
32. Saitoh K, Miura I, Takahashi N, et al. Fluorescence in situ hybridization of progenitor cells obtained by fluorescence-activated cell sorting for the detection of cells affected by chromosome abnormality trisomy 8 in patients with myelodysplastic syndromes. Blood. 1998;92:2886-2892.
33. Nilsson L, Astrand-Grundstrom I, Arvidsson I, et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood. 2000;96:2012-2021.